ReviewRenal failure2025
BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nephrotoxicity of Immune Checkpoint Inhibitors in Mice with a Human Immune System.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune kidney diseases usually arise from autoimmune system dysfunction and are characterized by production of autoantibodies. Several autoimmune kidney diseases are currently recognized, including lupus nephritis, antineutrophil cytoplasmic antibody-associated vasculitis, membranous nephropathy, IgA nephropathy. B-cell activating factor (BAFF), a member of the tumor necrosis factor family, serves as a critical regulator of humoral immunity. By binding to specific receptors on the surface of B cells, BAFF regulates their survival, proliferation, differentiation and antibody production, thereby playing a key role in the pathogenesis of autoimmune kidney diseases. Elevated serum BAFF levels, reported across multiple autoimmune diseases, promote aberrant B cell activation and autoantibody production. This review systematically illustrates the biology and immunology of BAFF, and further explores the role of BAFF in those autoimmune kidney diseases, aiming to provide a comprehensive insight into the BAFF molecule.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.